Diverse signalling by 5-hydroxytryptamine (5-HT) receptors.
暂无分享,去创建一个
[1] A M Krumins,et al. The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. , 1997, Molecular pharmacology.
[2] M. Ferrari,et al. Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.
[3] W. Sadee,et al. Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. , 1993, The Journal of biological chemistry.
[4] G. Milligan,et al. Up‐regulation of a constitutively active form of the β 2‐adrenoceptor by sustained treatment with inverse agonists but not antagonists , 1996, FEBS letters.
[5] D. Goldman,et al. Agonist-Promoted Down-Regulation and Functional Desensitization in Two Naturally Occurring Variants of the Human Serotonin1A Receptor , 1997, Neuropsychopharmacology.
[6] H. Bönisch,et al. Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. , 1999, Pharmacogenetics.
[7] R. Kohen,et al. Four 5‐Hydroxytryptamine7 (5‐HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron‐Exon Organization , 1997, Journal of neurochemistry.
[8] G. Milligan,et al. Regulation of G Protein Activation and Effector Modulation by Fusion Proteins between the Human 5-Hydroxytryptamine1AReceptor and the α Subunit of Gi1α: Differences in Receptor-Constitutive Activity Imparted by Single Amino Acid Substitutions in Gi1α , 1999 .
[9] P. Albert,et al. A conserved threonine residue in the second intracellular loop of the 5-hydroxytryptamine 1A receptor directs signaling specificity. , 1997, Molecular pharmacology.
[10] H. Manji,et al. A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization , 1997, Journal of neurochemistry.
[11] G. Martin,et al. The structure and signalling properties of 5-HT receptors: an endless diversity? , 1998, Trends in pharmacological sciences.
[12] T. Kenakin,et al. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.
[13] P. Pauwels. 5-HT 1B/D receptor antagonists. , 1997, General pharmacology.
[14] Y. Sugimoto,et al. Selective Coupling of Prostaglandin E Receptor EP3D to Gi and Gs through Interaction of α-Carboxylic Acid of Agonist and Arginine Residue of Seventh Transmembrane Domain (*) , 1995, The Journal of Biological Chemistry.
[15] R. Fischmeister,et al. The 5‐HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5‐HT4(c) receptor , 1998, British journal of pharmacology.
[16] A. Barr,et al. Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. , 1997, The Journal of biological chemistry.
[17] M. Zuscik,et al. Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.
[18] S. Rees,et al. Agonist occupation of an alpha2A-adrenoreceptor-Gi1alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins. Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry. , 1998, The Journal of biological chemistry.
[19] T. Kenakin. The classification of seven transmembrane receptors in recombinant expression systems. , 1996, Pharmacological reviews.
[20] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[21] Colleen M. Niswender,et al. RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.
[22] G. Milligan,et al. Insights into ligand pharmacology using receptor-G-protein fusion proteins. , 2000, Trends in pharmacological sciences.
[23] S. Maayani,et al. Novel actions of inverse agonists on 5-HT2C receptor systems. , 1999, Molecular pharmacology.
[24] Q. Yang,et al. Influence of G protein type on agonist efficacy. , 1999, Molecular pharmacology.
[25] E. sanders-Bush,et al. Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. , 1994, Molecular pharmacology.
[26] P. Pauwels,et al. Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Gαo protein , 1999, Neuropharmacology.
[27] Hui-yu Liu,et al. Quantitative Analysis of Formyl Peptide Receptor Coupling to Giα1, Giα2, and Giα3 * , 1999, The Journal of Biological Chemistry.
[28] T. Fields,et al. Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor. , 1994, Biochemistry.
[29] P. Leff,et al. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.
[30] J. Hagan,et al. Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719 , 1998, British journal of pharmacology.
[31] B. Kobilka,et al. G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[32] H. Bourne,et al. How receptors talk to trimeric G proteins. , 1997, Current opinion in cell biology.
[33] A. Brown,et al. Pharmacological characterisation of [35S]-GTPgammaS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes. , 1995, Journal of receptor and signal transduction research.
[34] J. Bockaert,et al. Cloning, expression and pharmacology of the mouse 5‐HT4L receptor , 1996 .
[35] M. Teitler,et al. Activating Mutations of the Serotonin 5‐HT2C Receptor , 1997, Journal of neurochemistry.
[36] M. Simon,et al. Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.
[37] J. Benovic,et al. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.
[38] P. Leff,et al. A three-state receptor model of agonist action. , 1997, Trends in pharmacological sciences.
[39] M. Millan,et al. S 14506: A novel, potent, high‐efficacy 5‐HT1A agonist and potential anxiolytic agent , 1992 .
[40] B. Kobilka,et al. GPCR–Gα fusion proteins: molecular analysis of receptor–G-protein coupling , 1999 .
[41] P. Pauwels,et al. Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors:Intrinsic activity and modulation by G-protein activation state , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[42] E. sanders-Bush,et al. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. , 1994, The Journal of biological chemistry.
[43] P. Pauwels,et al. Stimulated [35S]GTPγS binding by 5-HT1A receptor agonists in recombinant cell lines Modulation of apparent efficacy by G-protein activation state , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[44] C. Niswender,et al. Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity , 1999, Journal of neurochemistry.
[45] H Weinstein,et al. Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. , 1993, Journal of medicinal chemistry.
[46] D. Lovinger,et al. Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. , 1996, Molecular pharmacology.
[47] J. Bockaert,et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.
[48] M. Beer,et al. Characterisation of a cloned human 5-HT1A receptor cell line using [35S]GTPγS binding , 1997 .
[49] D. Colquhoun,et al. Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.
[50] G. Milligan,et al. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. , 1996, Molecular pharmacology.
[51] M. Göthert,et al. Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.
[52] S. Rees,et al. Hydrophobicity of residue351 of the G protein Gi1 alpha determines the extent of activation by the alpha 2A-adrenoceptor. , 1998, Biochemistry.
[53] R M Eglen,et al. 7TM receptors: the splicing on the cake. , 1999, Trends in pharmacological sciences.
[54] P. Pauwels,et al. How Efficacious are 5-HT1B/D Receptor Ligands: an Answer from GTPγS Binding Studies with Stably Transfected C6-glial Cell Lines , 1997, Neuropharmacology.
[55] R. Lefkowitz,et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.
[56] P. Pauwels,et al. Modulation of 5-HT1A receptor activation by its interaction with wild-type and mutant Gαi3 proteins , 2001, Neuropharmacology.
[57] S. Peroutka. Serotonin Receptor Variants in Disease: New Therapeutic Opportunities? , 1998, Annals of the New York Academy of Sciences.
[58] M. Millan,et al. Inhibition of the constitutive activity of human 5‐HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635 , 1997, British journal of pharmacology.
[59] B. Kobilka,et al. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.
[60] M. Teitler,et al. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.
[61] P. Chidiac,et al. Inverse agonist activity of beta-adrenergic antagonists. , 1994, Molecular pharmacology.
[62] R. Emeson,et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.
[63] A. Scheer,et al. The activation process of the alpha1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[64] D. Selley,et al. mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.
[65] R. Graham,et al. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.
[66] M. Caron,et al. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. , 1996, Canadian journal of physiology and pharmacology.
[67] R. Lefkowitz,et al. Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.
[68] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[69] P. Pauwels,et al. Ligand—Receptor Interactions as Controlled by Wild‐Type and Mutant Thr370Lys α2B‐Adrenoceptor—Gα15 Fusion Proteins , 2000 .
[70] P. Pauwels,et al. Facilitation of Constitutive α2A-Adrenoceptor Activity by Both Single Amino Acid Mutation (Thr373Lys) and Gαo Protein Coexpression: Evidence for Inverse Agonism , 2000 .